Serotype distribution and antimicrobial susceptibility of S. pneumoniae causing invasive disease in Thai children younger than 5 years old, 2000–2005

Changing trends in serotype distribution and antimicrobial susceptibility ofStreptococcus pneumoniaecausing invasive diseases in Central Thailand, 2009–2012

“…PCV13 provided higher coverage rate, similar to that of PCV15 in all age groups, and the coverage rate was highest in the group of children younger than 5 y (73.2%). In comparison with those reported by our network in 2000-2005 26 and 2006-2009, 27 serotype coverage reduced by 37% and 34% for PCV7 in children less than 5 y (from 73.9% and 70.3% to 46.4%).…”

“…Due to the emergence of serotype 19A in children younger than 5 y of age, the coverage rate of PCV7 in our network declined from 70% before 2009 26,27 to 46% after 2009. The PCV13 serotype coverage rate was highest in the youngest age group, up to the same range of that for PCV7 in the earlier period.…”

“…The current prevalence of S. pneumoniae serotype 19A among those ≤5 y was compared with previously published data from our collaborative network in 2000 to February 2009. 26,27 Statistical analysis was performed using χ2 and the Fisher exact test. The criteria for vaccine failure were adopted from a previous published study.…”

Incidence of Pneumococcal Bacteremia Requiring Hospitalization in Rural Thailand

“…Several cross-sectional and retrospective studies have documented the antimicrobial susceptibilities and serotype distributions of invasive and colonizing pneumococcal isolates in the region [3][4][5], but there are no published estimates of the incidence of pneumococcal disease. A recent study in Thailand demonstrated a high prevalence (60%) of nasopharyngeal carriage of Streptococcus pneumoniae among children aged !5 years [5], which suggests that the bacterium is common and that the prevalence of colonization is similar to that in countries before the introduction of pneumococcal conjugate vaccine and in other countries without routine vaccination.…”

Developing the Right Pneumococcal Vaccine for the Time and Place

“…The Global Alliance for Vaccines and Immunizations' Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) recently showed that in a surveillance project involving 15 resource limited nations, PCV-7 serotypes ranged from 6% to 79% of isolates, 3 while another recent study in Thailand found that 69% of isolates were PCV-7 serotypes. 4 Thus, the benefits of this vaccine, designed for North America and western Europe, may not extend to the rest of the world.…”